Table 1. Summary odds ratio of the association between HER3 over-expression and overall survival (OS) in gastrointestinal cancers.
| Studies | Number of studies | Heterogeneity test | Analysis model | OR (95% CI) | Hypothesis test | Begg's test | Egger's test | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q | P | Z | P | Z | P | t | P | ||||
| Overall | |||||||||||
| 3-year OS | 11 | 40.12 | 0.000 | Random-effects model | 1.33 (0.97–1.84) | 1.74 | 0.081 | 0.31 | 0.755 | 0.59 | 0.572 |
| 5-year OS | 10 | 41.72 | 0.000 | Random-effects model | 1.38 (1.04–1.82) | 2.26 | 0.024 | 1.25 | 0.210 | 0.96 | 0.364 |
| Gastric cancer | |||||||||||
| 3-year OS | 6 | 11.40 | 0.044 | Random-effects model | 1.69 (1.28–2.25) | 3.66 | 0.000 | 0.38 | 0.707 | 1.18 | 0.302 |
| 5-year OS | 5 | 15.67 | 0.003 | Random-effects model | 1.74 (1.26–2.41) | 3.32 | 0.001 | 2.20 | 0.027 | 7.28 | 0.005 |
| Colorectal cancer | |||||||||||
| 3-year OS | 5 | 12.34 | 0.015 | Random-effects model | 0.84 (0.48–1.47) | 0.62 | 0.536 | 0.73 | 0.462 | 0.46 | 0.679 |
| 5-year OS | 5 | 17.38 | 0.002 | Random-effects model | 1.05 (0.67–1.65) | 0.20 | 0.840 | 0.73 | 0.462 | 0.57 | 0.608 |